A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults

Pharmacotherapy
A C CrémieuxAZl10002 Study Group

Abstract

To investigate the steady-state pharmacokinetics of a triple combination tablet containing abacavir (ABC) 300 mg, lamivudine (3TC) 150 mg, and zidovudine (ZDV) 300 mg taken twice/day, and those of ABC 300 mg twice/day plus a double combination tablet containing 3TC 150 mg and ZDV 300 mg twice/day (ABC-COM). Open-label, crossover study. Two hospital-based clinical research units. Twelve men infected with human immunodeficiency virus-1. Steady-state pharmacokinetics of ABC, 3TC, and ZDV were assessed after dosing with ABC-COM and the triple combination tablet. Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour. The GM half-lives of ABC and ZDV were similar for both treatments, 1.69 versus 1.58 an...Continue Reading

Citations

Nov 25, 2003·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Lee D WilliamsDaniel R Doerge
Aug 9, 2008·Epidemiology and Infection·J E Truscott, N M Ferguson
Aug 9, 2008·Epidemiology and Infection·J E Truscott, N M Ferguson
Dec 12, 2001·HIV Medicine·J D Cartledge
Jan 29, 2002·Food Additives and Contaminants·C CrewsW Matthews
Nov 29, 2002·Food Additives and Contaminants·A GovarisN A Botsoglou
Jul 13, 2002·Food Additives and Contaminants·C G HamletD E Baxter
Nov 22, 2002·Food Additives and Contaminants·S KaravoltsosM Scoullos
Nov 22, 2002·Food Additives and Contaminants·T Berg, D Licht
May 18, 2005·Food Additives and Contaminants·I MarklinderM Olsen
Mar 19, 2008·Food Additives & Contaminants. Part A, Chemistry, Analysis, Control, Exposure & Risk Assessment·W SeefelderR H Stadler
Oct 24, 2007·Food Additives & Contaminants. Part A, Chemistry, Analysis, Control, Exposure & Risk Assessment·V VrommanN Waegeneers
Jul 8, 2009·Critical Reviews in Food Science and Nutrition·Ulf HammerlingNils-Gunnar Ilbäck
May 4, 2013·Toxicological Sciences : an Official Journal of the Society of Toxicology·Stephen Y XueTammy R Dugas
May 7, 2010·Therapeutic Drug Monitoring·Natella Y RakhmaninaMichael N Neely
May 23, 2003·Antimicrobial Agents and Chemotherapy·Robert DiCenzoUNKNOWN Adult AIDS Clinical Trials Group Protocol 368/886 Study Team
Oct 12, 2010·The Oncologist·Jeryl VilladolidThomas J George
May 16, 2008·Clinical Pharmacokinetics·Geoffrey J YuenGary E Pakes
May 17, 2003·Drugs·Tim Ibbotson, Caroline M Perry
Apr 17, 2014·The Pediatric Infectious Disease Journal·Quirine FillekesUNKNOWN ARROW Trial Team
Mar 14, 2013·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Déborah HirtJean-Marc Tréluyer
Feb 21, 2007·Expert Opinion on Pharmacotherapy·Philip Keiser, Naiel Nassar
Jun 1, 2014·Expert Opinion on Drug Metabolism & Toxicology·Diane E T BastiaansDavid M Burger
Sep 11, 2009·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Emilie FromentinRaymond F Schinazi
Jul 22, 2014·British Journal of Clinical Pharmacology·Floris FauchetDéborah Hirt
May 9, 2002·Expert Opinion on Pharmacotherapy·Philip Keiser, Naiel Nassar
Jul 24, 2013·Antimicrobial Agents and Chemotherapy·Floris FauchetDéborah Hirt
Nov 13, 2004·The Journal of Antimicrobial Chemotherapy·Alina S BergshoeffDavid M Burger
Dec 23, 2011·Clinical Pharmacology and Therapeutics·P KasiryeUNKNOWN ARROW Trial Team

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.